Neurizon Maps Path to Q3 2027 Data That Could Unlock 97% of ALS Patients

Neurizon advances NUZ-001 through HEALEY ALS Platform Trial with key milestones on track

In its April 2026 investor presentation, Neurizon Therapeutics (ASX: NUZ) outlined progress on its registrational Phase 2/3 trial for NUZ-001, a first-in-class oral small molecule targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). The company reported 8 patients now dosed in the HEALEY ALS Platform Trial since dosing commenced in February 2026, with 44 sites activated and 46 patients in master screening as of 9 April 2026.

The HEALEY trial represents a potential accelerated pathway to approval. Management highlighted that registrational Phase 2/3 data could support accelerated regulatory approval, positioning NUZ-001 as a treatment for the 97% of ALS patients whose disease is characterised by TDP-43 protein aggregation. This compares to the approximate 2% of patients with SOD1 mutations targeted by other drugs currently in development.

Neurizon aims to enrol 160 patients by Q3-Q4 2026, with topline data expected in Q3 2027. The presentation confirmed 13 patients have been assigned to the treatment regimen, indicating steady progression through the trial’s screening and randomisation processes.

NUZ-001 is an oral small molecule with validated blood-brain barrier penetration. The presentation noted that preclinical data demonstrate multi-pathway protein clearance activity, engaging both autophagy and proteasomal systems to address the core cellular dysfunction in ALS. The drug appeared safe and generally well-tolerated in exploratory Phase 1 and open-label extension studies involving a small population of 12 participants.

What is ALS and why does it represent a compelling commercial opportunity?

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease, is a progressive neurodegenerative condition that affects nerve cells in the brain and spinal cord. These motor neurones control voluntary muscle movement, and their degeneration leads to loss of muscle function, paralysis, and ultimately respiratory failure. The condition has limited treatment options and represents a high unmet medical need.

The dominant pathology in ALS involves TDP-43 protein aggregation, present in 97% of patients. TDP-43 is a protein that normally regulates gene expression, but in ALS it misfolds and accumulates in motor neurones, disrupting cellular function. By contrast, only approximately 2% of ALS patients have mutations in the SOD1 gene, and less than 1% have FUS mutations. Existing therapies have largely focused on these minority patient populations or provided only modest symptomatic benefit.

The ALS market is projected to reach US$1.28 billion by 2029, with a 15% annual sales growth rate. The presentation detailed a recent market value reference: Shionogi’s acquisition of global rights to RADICAVA (IV edaravone) and RADICAVA ORS (oral edaravone) from Tanabe Pharma for US$2.5 billion upfront, completed in April 2026. This transaction involved a commercial, revenue-generating ALS therapy franchise already in market, underscoring the value pharmaceutical companies place on established ALS treatments.

ALS Market Value Reference

Shionogi acquired global rights to RADICAVA for US$2.5 billion upfront in a transaction completed April 2026, demonstrating sustained commercial interest in ALS therapies.

NUZ-001’s focus on TDP-43 pathology positions it to address the dominant patient population that most existing treatments do not target. With an annual ALS patient population growth rate of 0.8% and significant unmet need for disease-modifying therapies, the addressable market opportunity remains substantial.

Elanco partnership underpins regulatory and commercial pathway

The presentation outlined Neurizon’s expanding relationship with Elanco across three pillars: the License Agreement, Strategic Investment, and the pending Supply Agreement. The License Agreement is an exclusive global licensing arrangement that provides worldwide rights to utilise Elanco’s intellectual property for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. This foundational agreement grants Neurizon access to animal safety data and manufacturing data critical to support future trials and potential regulatory approvals.

Through its participation in the December 2025 share placement, Elanco is now a top five shareholder in Neurizon, holding 3.09% of shares. Elanco has also appointed Justine Conway, its Global Head of Business Development, as a Board Observer. This strategic investment demonstrates Elanco’s confidence in the NUZ-001 programme and aligns its commercial interests with Neurizon’s clinical progress.

The Supply Agreement, expected to be executed in Q2 CY2026, remains a priority for both companies. Management noted that this agreement will provide access to long-term, scalable GMP-compliant monepantel — the active pharmaceutical ingredient in NUZ-001. Both parties are constructively working on finalising contractual terms to support Neurizon’s commercial supply requirements. The company confirmed that a recent shipment of monepantel has secured the supply required through the end of the HEALEY trial.

The Elanco relationship de-risks the regulatory approval process by providing manufacturing data, intellectual property licensing, and commercial-scale supply capabilities. These elements position Neurizon to move from trial completion to potential commercialisation with reduced execution risk.

Key milestones timeline for 2026-2027

The presentation detailed near-term and long-term trial execution milestones, with enrolment completion targeted for Q3-Q4 2026 and topline data expected in Q3 2027. The company outlined anticipated trial execution updates, including site activation confirmations, enrolment milestones (such as 50% enrolled and enrolment complete), and completion milestones (Last Patient In and Last Patient Last Visit).

The HEALEY ALS Platform Trial employs a 36-week double-blind, placebo-controlled period with 3:1 randomisation (NUZ-001 versus placebo), followed by a 36-week active treatment extension period. The primary endpoint measures change from baseline through Week 36 in disease severity using the ALSFRS-R total score and survival. Secondary endpoints include change in respiratory function via slow vital capacity and survival through Week 36.

Funding secured to complete HEALEY trial with multiple non-dilutive options

The presentation outlined Neurizon’s three-pillar funding strategy designed to minimise shareholder dilution whilst securing adequate capital to complete the HEALEY trial. Cash as at 31 March 2026 stood at $16.7 million, with net cash of $11.1 million after accounting for convertible note debt of $5.6 million.

The funding strategy comprises:

1. Placement and Entitlement Offer: The company raised approximately $7.1 million through a share placement at $0.08 per share in December 2025, with Elanco participating. A subsequent 2-for-5 entitlement offer at $0.08 per share raised approximately $5.9 million from eligible shareholders through entitlement subscriptions and oversubscriptions.

2. Research & Development Tax Rebate: Neurizon’s Advance and Overseas Finding (AOF) approval provides a cash rebate of at least 43.5% on HEALEY trial spend. The AOF is binding on the Australian Tax Office and AusIndustry, providing a significant non-dilutive funding source. The company received approximately $6 million in R&D refunds for FY2025.

3. Convertible Note Facility: A $20 million convertible note facility with Obsidian Global GP, LLC provides additional flexibility. The company drew $5 million in February 2026, with the remaining $15 million available as an option but with no obligation to draw. The facility includes trading restrictions to protect shareholder and optionholder interests.

Management emphasised that the funding strategy has been developed with a focus on protecting shareholder interests through flexible funding instruments and minimising dilution. The ability to finance the R&D rebate receivables and the option to displace the convertible note facility if appropriate provide additional financial flexibility.

NUZ-001’s mechanism and broader pipeline potential

The presentation detailed NUZ-001’s mechanism-driven approach, which targets proteostasis and addresses core cellular dysfunction rather than a single disease-specific pathway. New preclinical data demonstrate that NUZ-001 increases activity of multiple protein clearance pathways in neuronal models, engaging both autophagy and proteasomal systems. This disease-agnostic mechanism positions NUZ-001 to potentially address multiple neurodegenerative conditions characterised by protein aggregation.

Management outlined target proteins and associated diseases where NUZ-001 may demonstrate therapeutic potential:

• TDP-43: ALS, Alzheimer’s Disease, Parkinson’s Disease, Frontotemporal Dementia, Chronic Traumatic Encephalopathy
• Amyloid beta: Alzheimer’s Disease, Parkinson’s Disease
• Tau: Alzheimer’s Disease, Parkinson’s Disease, Frontotemporal Dementia, Chronic Traumatic Encephalopathy, Progressive Supranuclear Palsy
• Alpha-synuclein: Alzheimer’s Disease, Parkinson’s Disease
• mHTT: Huntington’s Disease

The company’s patent protection extends to 2041 in Australia and the United States, with patents pending in the European Union and Japan. NUZ-001 has received US Orphan Drug Designation, providing 7 years of market exclusivity, and European Orphan Medicinal Product Designation, providing 10 years of market exclusivity. These regulatory designations provide commercial protection beyond patent expiry.

The presentation noted that patent claims cover key analogues of monepantel, optimised dosing and formulation strategies, and monepantel use in neurodegenerative and mTOR-related diseases. Protected jurisdictions include Australia, Canada, China, the European Union, Switzerland, Hong Kong, Japan, South Korea, and the United States.

The company is working to broaden the pipeline to other neurodegenerative diseases through ongoing preclinical studies. Management stated that the potential application of NUZ-001 beyond ALS is being developed through a preclinical programme, with preclinical updates expected in Q2 2026.

Investment thesis and upcoming catalysts

Neurizon’s presentation highlighted the company’s transition from preclinical development to registrational Phase 2/3 execution. The HEALEY trial is underway, with 8 patients dosed and 44 sites activated. The Elanco partnership provides regulatory and commercial de-risking through access to manufacturing data, intellectual property, and commercial-scale supply. Funding has been secured to complete the trial, with significant non-dilutive components including R&D rebates and a committed convertible note facility providing optionality.

The next 12-18 months will deliver critical enrolment and regulatory milestones. Near-term catalysts investors should monitor include:

1. Elanco Commercial Supply Agreement — Q2 CY2026
2. HEALEY enrolment milestones — 50% and 100% enrolment updates
3. Preclinical updates on broader indications — Q2 2026
4. EMA Scientific Advice preparation
5. PMDA (Japan) regulatory consultation
6. Liquid formulation PK study initiation — Q2 2026

The presentation also outlined ongoing efforts to expand partnerships with patient associations and engage with potential strategic partners at major international conferences and partnering events, including CNS Partnering and Target ALS.

Company Promise

“Accelerating Patient Hope and Access to Innovative ALS Treatment.”

With the HEALEY trial progressing on schedule, regulatory pathways clear, and funding secured, Neurizon is positioned to deliver data in Q3 2027 that could support accelerated approval for a treatment targeting the dominant ALS patient population.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare and biotech news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements drop.